Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

NCT01109069 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT01109069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01109069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2010
Completion date
April 26, 2019
Enrollment
199 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma, b-cell chronic lymphocytic leukemia, b-cell diffuse lymphoma, burkitt lymphoma, diffuse well-differentiated lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, non-hodgkin's lymphoma, small lymphocytic lymphoma, waldenstrom macroglobulinemia